NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
Clinical Trials
39 trialsNCT04225390 2026-02-10
PROMIT
University of Erlangen-Nürnberg Medical School
Phase 2 Completed
NCT03023124 2024-12-09
STRADA
Italian Sarcoma Group
Phase 2 Completed
NCT02181738 2023-11-28
CheckMate 205
Bristol-Myers Squibb
Phase 2 Completed
NCT01152788 2023-08-22
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT05898451 2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2 Completed
NCT02292979 2022-08-19
BREACH
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT00000626 2021-10-27
Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2 Completed
NCT01132807 2021-06-14
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02505269 2020-08-24
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00416832 2020-03-26
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
Martin-Luther-Universität Halle-Wittenberg
Phase 2 Completed
NCT01551459 2019-10-29
SUAVE
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2 Completed
NCT01100528 2019-02-26
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01569204 2018-10-29
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
University of Cologne
Phase 2 Completed
NCT00369681 2018-08-27
Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01534078 2018-02-20
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT01693068 2018-01-05
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
EMD Serono
Phase 2 Completed
NCT01143402 2017-07-26
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT00802880 2017-02-13
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
Washington University School of Medicine
Phase 2 Completed
NCT00936221 2016-03-14
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
AstraZeneca
Phase 2 Completed
NCT01028222 2015-12-30
TEAM
Novartis
Phase 2 Completed
NCT00837148 2015-11-20
Sorafenib and Dacarbazine in Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01376713 2015-10-06
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
Medical University of Vienna
Phase 2 Completed
NCT01681212 2015-06-11
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT00110994 2015-06-08
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 2 Completed
NCT00492297 2014-10-31
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
Bayer
Phase 2 Completed
NCT00533702 2014-08-01
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
Eli Lilly and Company
Phase 2 Completed
NCT00004010 2014-02-26
Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease
Children's Oncology Group
Phase 2 Completed
NCT00002791 2014-01-24
Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00504504 2013-07-09
Rituximab and ABVD for Hodgkin's Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01404936 2013-02-01
Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00002669 2012-07-02
Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00794235 2010-01-08
Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine
University of Zurich
Phase 2 Completed
NCT00911443 2009-07-09
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
sigma-tau i.f.r. S.p.A.
Phase 2 Completed
NCT00308607 2009-04-03
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
University of Turku
Phase 2 Completed
NCT00070642 2009-02-10
CPG 7909 Injection in Melanoma
Pfizer
Phase 2 Completed
NCT00099970 2008-08-05
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
Facet Biotech
Phase 2 Completed
NCT00066196 2008-01-15
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
MedImmune LLC
Phase 2 Completed